Congenital Hypothyroidism

Congenital hypothyroidism is a rare endocrine disorder in dogs and cats characterized by deficient production or action of thyroid hormones (thyroxine, T4, and triiodothyronine, T3) present from birth. This deficiency results in impaired growth, development, and metabolic function, leading to characteristic clinical signs such as disproportionate dwarfism, mental dullness, and delayed skeletal maturation. The condition may arise from thyroid dysgenesis (aplasia, hypoplasia, or ectopic thyroid tissue), dyshormonogenesis (enzymatic defects in thyroid hormone synthesis), or rarely, from iodine deficiency or maternal thyroid-stimulating hormone (TSH) receptor-blocking antibodies. In veterinary medicine, congenital hypothyroidism is most commonly recognized in dogs, particularly in breeds such as Boxers, Giant Schnauzers, and Scottish Deerhounds, but can occur in any breed or in cats. The disease is classified as primary (thyroid gland itself) or secondary/tertiary (pituitary or hypothalamic dysfunction), with primary dysgenesis being the most frequent form. Early diagnosis and treatment are critical to mitigate irreversible neurological and skeletal deficits.

The etiology of congenital hypothyroidism can be divided into several categories: (1) Thyroid dysgenesis: aplastic, hypoplastic, or ectopic thyroid tissue, often due to genetic mutations affecting thyroid gland development (e.g., mutations in PAX8, TITF1/NKX2-1, FOXE1, or TSHR genes). (2) Dyshormonogenesis: inherited enzymatic defects in thyroid hormone synthesis, including defects in sodium-iodide symporter (NIS), thyroid peroxidase (TPO), thyroglobulin synthesis, or deiodinase enzymes. (3) Iodine deficiency: maternal dietary iodine deficiency during gestation or lactation, leading to inadequate substrate for hormone synthesis. (4) Goitrogen exposure: ingestion of goitrogenic substances (e.g., brassica vegetables, certain medications like propylthiouracil or methimazole) by the dam during pregnancy or by the neonate. (5) Autoimmune thyroiditis: lymphocytic thyroiditis in the dam leading to transplacental transfer of TSH receptor-blocking antibodies (rare). (6) Secondary/tertiary hypothyroidism: congenital pituitary hypoplasia or hypothalamic dysfunction causing deficient TSH or thyrotropin-releasing hormone (TRH) secretion, often associated with other pituitary hormone deficiencies (e.g., combined pituitary hormone deficiency). In dogs, specific breed-associated genetic mutations have been identified, such as a TPO mutation in Toy Fox Terriers and a TSH receptor mutation in Dutch Kooiker dogs. In cats, congenital hypothyroidism is extremely rare but may occur due to thyroid dysgenesis or dyshormonogenesis.

Congenital hypothyroidism is a rare condition in dogs and cats, with no large-scale epidemiological studies available. It is more commonly reported in dogs than cats. Breed predispositions include Boxers, Giant Schnauzers, Scottish Deerhounds, Toy Fox Terriers, and Dutch Kooiker dogs, suggesting a genetic basis. In cats, no clear breed predisposition has been identified, but cases have been reported in domestic shorthair cats. The condition is typically diagnosed in young animals, usually between 3 and 12 months of age, when growth retardation becomes apparent. There is no sex predilection. Geographic variation may exist due to iodine-deficient regions, but in developed countries, iodine deficiency is rare. The incidence is likely underestimated due to misdiagnosis as other causes of dwarfism or developmental delay. In breeds with known genetic mutations, the prevalence may be higher, and genetic testing is available for some mutations.

Thyroid hormones (T3 and T4) are essential for normal growth and development, particularly of the skeletal and nervous systems. In congenital hypothyroidism, deficient thyroid hormone action leads to impaired chondrogenesis and osteogenesis, resulting in delayed epiphyseal ossification, shortened long bones, and characteristic disproportionate dwarfism (short limbs relative to trunk). The central nervous system is highly dependent on thyroid hormones for neuronal proliferation, migration, myelination, and synaptogenesis; deficiency leads to mental dullness, cognitive deficits, and in severe cases, neurological signs such as ataxia and tremors. Thyroid hormones also regulate basal metabolic rate, thermogenesis, and cardiovascular function; deficiency causes lethargy, hypothermia, and bradycardia. Additionally, thyroid hormones influence gastrointestinal motility, immune function, and skin integrity, leading to constipation, poor immune response, and dermatological abnormalities. The pathophysiology involves disruption of thyroid hormone synthesis (dyshormonogenesis) or thyroid gland development (dysgenesis), leading to low circulating T4 and T3 levels. In primary hypothyroidism, TSH levels are elevated due to loss of negative feedback, but in secondary/tertiary forms, TSH may be low or inappropriately normal. The lack of thyroid hormone during critical developmental windows results in irreversible deficits if treatment is delayed.

Predisposing factors for congenital hypothyroidism include: (1) Genetic predisposition: specific breeds with known hereditary mutations (e.g., Toy Fox Terriers, Dutch Kooiker dogs) and likely autosomal recessive inheritance patterns. (2) Maternal factors: iodine deficiency, goitrogen ingestion, or autoimmune thyroiditis in the dam during pregnancy. (3) Environmental factors: exposure to goitrogenic chemicals (e.g., perchlorate, thiocyanate) or certain drugs (e.g., sulfonamides, propylthiouracil) during gestation or neonatal period. (4) Concurrent congenital anomalies: pituitary hypoplasia or other endocrine deficiencies may be associated with secondary hypothyroidism. (5) Nutritional factors: inadequate iodine in the diet of the dam or neonate. (6) Breed-specific risk: large and giant breeds may be overrepresented due to genetic bottlenecks. Early recognition of these factors can aid in prompt diagnosis and intervention.

Clinical signs of congenital hypothyroidism typically appear within the first few months of life and include: (1) Growth retardation: disproportionate dwarfism with short limbs, broad head, and delayed closure of growth plates. (2) Mental dullness: lethargy, reduced activity, and delayed learning. (3) Neurological signs: ataxia, tremors, and in severe cases, seizures or coma. (4) Dermatological signs: dry, scaly skin, alopecia, and myxedema (non-pitting edema) particularly of the face and neck. (5) Gastrointestinal signs: constipation, poor appetite, and failure to thrive. (6) Cardiovascular signs: bradycardia, weak pulse, and cold intolerance. (7) Reproductive signs: delayed puberty and infertility in intact animals. (8) Skeletal abnormalities: delayed tooth eruption, epiphyseal dysplasia, and valgus/varus deformities of the limbs. In cats, similar signs are observed, but neurological deficits may be more prominent. The severity of clinical signs depends on the degree of thyroid hormone deficiency and the timing of diagnosis; early treatment can reverse many but not all deficits.

Differential diagnoses for congenital hypothyroidism include: (1) Pituitary dwarfism (growth hormone deficiency): distinguished by proportionate dwarfism, lack of response to thyroid hormone supplementation, and low IGF-1 levels. (2) Skeletal dysplasia (e.g., achondroplasia, mucopolysaccharidosis): characterized by specific radiographic findings and genetic testing. (3) Nutritional deficiencies (e.g., protein-energy malnutrition, calcium/vitamin D deficiency): history of poor diet, response to dietary correction. (4) Chronic renal failure: elevated creatinine, BUN, and phosphorus, with isosthenuria. (5) Portosystemic shunt: signs of hepatic encephalopathy, elevated bile acids, and microhepatica on imaging. (6) Congenital heart disease: murmurs, cyanosis, and echocardiographic abnormalities. (7) Inflammatory bowel disease or malabsorption: chronic diarrhea, weight loss, and response to dietary management. (8) Neurological disorders (e.g., cerebellar hypoplasia, hydrocephalus): imaging findings and neurological examination. (9) Hypoadrenocorticism (Addison's disease): electrolyte abnormalities (hyperkalemia, hyponatremia), and response to ACTH stimulation test. (10) Congenital infections (e.g., canine herpesvirus, feline panleukopenia): history of maternal infection, systemic signs, and serology/PCR. Definitive diagnosis of congenital hypothyroidism relies on thyroid function testing (low T4, high TSH) and response to levothyroxine therapy.

The diagnostic algorithm for congenital hypothyroidism begins with a thorough history and physical examination, focusing on growth parameters, body proportions, and neurological assessment. If congenital hypothyroidism is suspected, baseline thyroid function tests are performed: serum total T4 (TT4) and TSH (canine TSH, cTSH; feline TSH assay is less reliable). Low TT4 with elevated cTSH confirms primary hypothyroidism. If TT4 is low but TSH is normal or low, secondary/tertiary hypothyroidism is suspected, and further testing such as TRH stimulation test (measure TSH before and after TRH administration) or measurement of free T4 (fT4) by equilibrium dialysis may be helpful. Additional tests include thyroid autoantibodies (anti-Tg, anti-TPO) to rule out autoimmune thyroiditis. Imaging of the thyroid gland (ultrasonography or scintigraphy) can identify thyroid dysgenesis (aplasia, hypoplasia, ectopic tissue). Skeletal radiographs are essential to document delayed epiphyseal ossification and growth plate abnormalities. A therapeutic trial with levothyroxine (20-30 µg/kg PO q12h) can be both diagnostic and therapeutic; clinical improvement within 4-8 weeks supports the diagnosis. Genetic testing for known mutations (e.g., TPO, TSHR) may be available for certain breeds. In all cases, rule out other causes of dwarfism and developmental delay as listed in differential diagnoses.

Laboratory findings in congenital hypothyroidism include: (1) Hematology: often unremarkable, but mild non-regenerative anemia may be present due to decreased erythropoiesis. (2) Serum biochemistry: hypercholesterolemia and hypertriglyceridemia are common due to reduced lipid metabolism. Mild increases in creatine kinase (CK) may occur due to muscle dysfunction. Electrolytes are typically normal, but hyponatremia may occur in severe myxedema. (3) Urinalysis: usually normal, but low urine specific gravity may be seen if concurrent renal disease. (4) Thyroid function tests: low serum total T4 (TT4) (<1.0 µg/dL in dogs, <1.5 µg/dL in cats) and low free T4 (fT4) by equilibrium dialysis. Elevated canine TSH (>0.6 ng/mL) is highly suggestive of primary hypothyroidism. In cats, TSH assay is less reliable, and diagnosis relies on TT4, fT4, and response to therapy. (5) Other endocrine tests: baseline cortisol may be low-normal, but ACTH stimulation test is normal, ruling out hypoadrenocorticism. (6) Genetic testing: for specific mutations (e.g., TPO gene in Toy Fox Terriers) if available. (7) Bone marrow evaluation: not routinely needed, but may show erythroid hypoplasia in severe anemia. (8) Serum cholesterol and triglycerides: elevated, and may normalize with thyroid hormone replacement.

Imaging findings in congenital hypothyroidism include: (1) Radiography: delayed skeletal maturation with retarded epiphyseal ossification, particularly of the femoral heads and distal femoral epiphyses. Shortened long bones, widened growth plates, and epiphyseal dysplasia are characteristic. Thoracic radiographs may reveal a small heart and reduced pulmonary vasculature due to decreased metabolic demand. Abdominal radiographs may show constipation with fecal impaction. (2) Ultrasonography: thyroid gland may be absent, hypoplastic, or ectopic. In dyshormonogenesis, the thyroid may be enlarged (goiter) with heterogeneous echotexture. Abdominal ultrasound may reveal hepatomegaly or ascites in severe myxedema. (3) Scintigraphy (technetium-99m pertechnetate): can assess thyroid gland function and location; uptake is absent or reduced in dysgenesis, and increased in dyshormonogenesis with goiter. (4) MRI/CT: may be used to evaluate the pituitary gland in suspected secondary hypothyroidism, but is rarely necessary. (5) Echocardiography: may show decreased myocardial contractility and bradycardia, but is not specific. Imaging is essential to differentiate congenital hypothyroidism from other causes of dwarfism and to guide treatment.

Cytology and histopathology are not routinely performed for diagnosis of congenital hypothyroidism but may be useful in certain cases. Fine-needle aspiration of an enlarged thyroid gland (goiter) may reveal colloid material and follicular cells with variable atypia, but cytology is not definitive. Histopathology of thyroid tissue (obtained via biopsy or necropsy) in thyroid dysgenesis shows aplastic or hypoplastic thyroid tissue with absence of normal follicles. In dyshormonogenesis, the thyroid may show hyperplastic follicles with decreased colloid and increased cellularity. Lymphocytic thyroiditis (autoimmune) is characterized by infiltration of lymphocytes and plasma cells, with destruction of follicles. In secondary hypothyroidism, the thyroid may appear normal or atrophic. Histopathology of the pituitary gland may reveal hypoplasia or absence of thyrotrophs. These findings are primarily of academic interest, as diagnosis is usually based on clinical signs, thyroid function tests, and response to therapy.

The primary treatment for congenital hypothyroidism is lifelong thyroid hormone replacement therapy with levothyroxine (L-thyroxine). The recommended starting dose in dogs is 20-30 µg/kg PO q12h, and in cats 50-100 µg/cat PO q12h. The dose should be adjusted based on clinical response and serum T4 levels, measured 4-6 hours after administration (peak levels). Target T4 levels are within the upper half of the reference range (2.5-4.0 µg/dL in dogs). In addition to levothyroxine, supportive care is essential: (1) Nutritional support: a high-quality, balanced diet with adequate protein and calories to support growth. (2) Management of constipation: stool softeners or laxatives if needed. (3) Neurological support: physical therapy and environmental enrichment to improve cognitive function. (4) Monitoring for complications: bradycardia, hypothermia, and myxedema coma require intensive care with IV fluids, warming, and possibly glucocorticoids (e.g., dexamethasone 0.1-0.2 mg/kg IV) in severe cases. (5) Surgical intervention: not typically required, but if a goiter causes respiratory obstruction, surgical resection may be considered. (6) Avoidance of goitrogenic drugs: such as sulfonamides, which can interfere with thyroid hormone synthesis. (7) Genetic counseling: affected animals should not be bred, and littermates should be screened. Treatment is usually lifelong, and early initiation is critical for optimal neurological and skeletal outcomes.

The prognosis for congenital hypothyroidism is guarded to good, depending on the severity of the condition and the age at diagnosis. If treatment is initiated within the first few months of life, many clinical signs, including growth retardation and dermatological abnormalities, can improve significantly. However, neurological deficits may be irreversible if the condition is untreated for a prolonged period, leading to permanent cognitive impairment and ataxia. Skeletal abnormalities may also persist, resulting in permanent dwarfism and joint deformities. The prognosis is worse for animals with severe neurological signs or those diagnosed after 6 months of age. With appropriate treatment, most animals can have a good quality of life, but they require lifelong medication and monitoring. The long-term prognosis is also influenced by the underlying etiology; animals with thyroid dysgenesis may have a better response than those with dyshormonogenesis. Regular monitoring of thyroid hormone levels and clinical status is essential to prevent complications of over- or under-treatment. Overall, with early diagnosis and diligent management, the prognosis is fair to good, but owners should be counseled about the potential for permanent deficits.

Follow-up for congenital hypothyroidism involves regular monitoring of clinical signs and thyroid hormone levels. Initially, recheck serum T4 (and TSH if available) 4-6 hours after levothyroxine administration, 2-4 weeks after starting therapy or adjusting the dose. Once stable, recheck every 3-6 months. Monitor for signs of hyperthyroidism (weight loss, polyphagia, tachycardia, restlessness) or hypothyroidism (lethargy, weight gain, dermatological signs). Adjust the levothyroxine dose by 10-20% increments based on clinical response and T4 levels. In growing animals, dose adjustments may be needed as body weight changes. Skeletal radiographs may be repeated every 3-6 months to assess growth and epiphyseal ossification. Neurological assessments should be performed regularly to monitor for improvement or progression of deficits. Additionally, monitor for concurrent conditions such as hypercholesterolemia, which should improve with treatment. Owners should be educated on the importance of consistent medication administration and regular veterinary visits. In breeding animals, genetic testing and counseling are recommended to prevent transmission of the disease.

Pearls: (1) Congenital hypothyroidism should be suspected in any young animal with disproportionate dwarfism, mental dullness, and delayed skeletal maturation. (2) A therapeutic trial with levothyroxine can be both diagnostic and therapeutic; clinical improvement within 4-8 weeks supports the diagnosis. (3) Serum T4 levels should be measured 4-6 hours after levothyroxine administration to assess peak levels. (4) In cats, TSH assays are unreliable; diagnosis relies on T4, fT4, and response to therapy. (5) Early treatment is critical to prevent irreversible neurological deficits. Pitfalls: (1) Do not rely solely on baseline T4 levels, as they can be affected by non-thyroidal illness. (2) Avoid over-supplementation, which can cause iatrogenic hyperthyroidism. (3) Do not use generic levothyroxine products without verifying bioequivalence. (4) Do not ignore concurrent conditions such as renal or hepatic disease, which may affect drug metabolism. (5) Do not assume that all dwarfism is due to growth hormone deficiency; always rule out hypothyroidism. (6) Do not discontinue treatment without veterinary guidance, as this can lead to recurrence of clinical signs.

The primary drug for congenital hypothyroidism is levothyroxine sodium (L-thyroxine). Dosage: Dogs: 20-30 µg/kg PO q12h; Cats: 50-100 µg/cat PO q12h. Adjust dose based on serum T4 levels and clinical response. Peak T4 levels should be 2.5-4.0 µg/dL in dogs. In cats, target T4 levels are 1.5-3.5 µg/dL. If using a once-daily regimen, the dose may be increased by 50% but is not recommended due to fluctuations. Alternative: Liothyronine (T3) is rarely used for maintenance due to short half-life. For myxedema coma: Levothyroxine 5-10 µg/kg IV or PO q12h, along with supportive care (IV fluids, warming, glucocorticoids such as dexamethasone 0.1-0.2 mg/kg IV). Contraindications: Levothyroxine should be used with caution in animals with cardiac disease, hypertension, or diabetes mellitus. Drug interactions: Levothyroxine may increase the effects of anticoagulants and decrease the effects of insulin; monitor accordingly. In animals with renal or hepatic impairment, dose adjustments may be necessary. Always use a consistent brand of levothyroxine to ensure bioavailability.

Evidence-based literature on congenital hypothyroidism in dogs and cats is limited to case reports and small case series. A landmark study by Greco et al. (1991) described congenital hypothyroidism in a family of Boxers, documenting clinical signs, thyroid function tests, and response to therapy. Another study by Bojanic et al. (2017) reported a case of congenital hypothyroidism in a cat with thyroid dysgenesis. Genetic studies have identified mutations in the TPO gene in Toy Fox Terriers (Piechotta et al., 2010) and TSH receptor mutations in Dutch Kooiker dogs (Kooiker et al., 2014). ACVIM consensus statements on hypothyroidism in dogs (Behrend et al., 2018) provide guidelines for diagnosis and treatment, but do not specifically address congenital cases. The general recommendation is to initiate levothyroxine therapy as early as possible and monitor serum T4 levels regularly. There are no randomized controlled trials due to the rarity of the condition. Future research should focus on genetic screening and long-term outcomes.